H.C. Wainwright 26th Annual Global Investment Conference Presentation
For Fiscal Year Ending Jun 30, 2024
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
iBio Inc.
1750 Sorrento Valley Road
Suite 200
San Diego, CA 92121
T: 979-446-0027
info@ibioinc.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.